Bio-dar Ltd.

Other

Yeda Research and Develpment & Co. Ltd

Izun Pharmaceuticals Corporation

Avner Rotman

Yoav Blatt

David Cohen

Eugene Kimmelman

Oded Friedman

Eugene Kimelman

Oded Arad

Yehuda Mazur

Gabriel Nussbaum

Rika Pinto

Amy Debra Rosenbluh

Gabriel Jay Nussbaum

An aspect of embodiments of the invention relates to providing novel therapeutic compositions comprising herbal extracts of the plant species, and. The compositions exhibit increased therapeutic activity for treatment of various inflammatory diseases, in particular, inflammatory diseases of mucosa or skin relative to previously identified compositions. In addition the compositions exhibit increased solubility relative to previously identified compositions. In an embodiment of the invention, the ratio ofis 7:1:2. An embodiment of the invention provides methods for preparing an aqueous therapeutic composition comprising extracts of the aforementioned plant species, using at least two extractions.

Methods for preparing anti-inflammatory herbal extracts comprisingand

There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated isoflavone-enriched fraction or mixture of such fractions, comprising at least one granulated isoflavone-enriched fraction and at least one carrier, diluent or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 75 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, at pH 6.8, and a temperature of 37&#xb0; C. A process for the preparation of such a formulation is also provided.

Microencapsulated and controlled-release formulations of isoflavone from enriched fractions of soy and other plants

There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated herb, comprising a granulated herb and at least one carrier, adjuvant or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37&deg; C. A process for the preparation of such formulation is also provided.

Microencapsulated and controlled-release herbal formulations

There are provided orally-administrable formulations for the controlled release of granulated garlic, comprising particles of granulated garlic coated with a film comprising a mixture of at least one water soluble polymer and at least one water insoluble polymer, said at least one water soluble polymer and at least one water insoluble polymer being present in a ratio that produces a substantially zero order linear release pattern of at least one active ingredient. Preferably, the formulations are characterized in that the total in vitro dissolution time of said formulations required for release of 75% of the Allicin available from said formulations based upon the total amount of alliin initially present in said formulations is between about 4 and about 12 hours, as determined by U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37&deg; C. A process for preparing the formulations of the invention is also disclosed.

Controlled-release garlic formulations

The present invention relates to controlled/extended release oral dosage forms of chromium picolinate. Chromium picolinate is a common and effective biologically active form of chromium. As such, it has beneficial nutritional and therapeutic effects including improved insulin metabolism and lipid lowering activity. The controlled dosage form of the present invention can be provided in various ways, including matrix formulations such as matrix tablets or multiparticulate formulations like micro capsules or coated pellets put into hard gelatin capsules. This provides effective drug delivery for extended periods of time, at relatively stable, optimal plasma peak values, with minimal undesirable side effects. The invention provides effective controlled/extended release oral dosage formulations of chromium picolinate and processes for their preparation.

Controlled release chromium picolinate

Very small particles of flavoring materials which are labile when subjected to both heat and an aqueous medium are coated with a coating material containing hydrogenated castor oil and having a melting point of from about 80.degree. to about 100.degree. C. The coating layer remains stable during the first minutes of the baking process, when the concentration of water in the dough or batter is relatively high. After several minutes, when most of the water in the dough or batter has evaporated and the temperature increases to about 100.degree. C., the coating layer or layers melt away. Within a few minutes thereafter, the active ingredient is exposed within the product. Alternatively, a leavening agent may be used wihtin the capsule which will release a gas at the predetermined temperature and cause rupture of the microencapsulation.

Heat stabilized flavoring agents coated with hydrogenated castor oil

Any orally administrable medicament is prepared into a dosage form which eliminates the unpleasant taste and mouth feel of the medicament and is easily and pleasantly ingested even by children, by microencapsulating the medicament into microcapsules of less than 300 microns diameter, and embedding the microcapsules into a soft, sweet, palatable matrix, such as chocolate.

Microencapsulated medicament in sweet matrix

A tablet for oral adminstration of a sustained-release medication is formed by compressing microcapsules of the active principle. The microcapsules are of a size range between about 5 and 300 microns and comprise particles of active principle coated with a thin, flexible layer of sustained release material. The sustained-release material contains about 15-30% by weight thereof of plasticizer and is coated in an amount corresponding to 10-25% of the weight of the active material. Excipients causing disintegration of the tablet after administration can be uniformly mixed with the microcapsules prior to compression.

Sustained release tablets made from microcapsules

The invention relates to derivatives of fluorescein and to their production. The compounds are of value in determining the intracellular pH. Thus there may be obtained fluorescent living cells with a comparatively stable level of fluorescence. The novel fluorescein compounds can be used for other labelling purposes in biology and biochemistry.

Derivatives of fluorescein

Process for the production of hydroxylated derivatives of cholesterol and 7-dehydrocholesterol which comprises subjecting a saturated unsubstituted or substituted derivative of cholestane, dissolved in a suitable solvent, in the presence of peracetic acid, to irradiation with ultra-violet radiation of a wavelength below 350m.mu. , or heating in a suitable solvent, separating the reaction products, which if desired, are converted to other derivatives, and recovering the residue of the starting material. Novel derivatives are obtained and these are: 3.beta.-acetoxy,25-hydroxy,5.alpha.-cholestane; 3.beta.-acetoxy, 5.alpha.,25-dihydroxy cholestane; 3.beta.,5.alpha.,25-trihydroxy cholestane; 3-keto, 5.alpha.,25-dihydroxy cholestane; 3-keto,25-hydroxy-.DELTA..sup.4 -cholestane; 3.beta.,25-diacetoxy-5.alpha.-hydroxy-cholestane; 3.beta.-acetoxy, 25-trichloroacetoxy-5.alpha.-hydroxy-cholestane, 25-trichloroacetoxy-cholesterol and 25-acetoxy-cholesterol.

Growing community of inventors

Rehovot, Israel

Avner Rotman